Status:
UNKNOWN
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers
Lead Sponsor:
Assiut University
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
To examine the efficacy of Montelukast as an adjunct to INCS in patients with allergic rhinitis.
Detailed Description
Allergic rhinitis (AR) is a non-infectious inflammatory disease occurring in nasal mucosa with nasal itching, nasal congestion, rhinorrhea, and sneezing as its main clinical symptoms, which are induce...
Eligibility Criteria
Inclusion
- Adult patients (aged 18 years and over) with AR. Clinical diagnosis of Allergic Rhinits Must be able to swallow tablets
Exclusion
- Bronchial Asthma patients. Patients already on Antihistamine combined treatment Patients who are allergic to this medication Advanced liver or kidney diseases.
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05381207
Start Date
October 1 2022
End Date
October 1 2024
Last Update
May 19 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.